[cnxvideo id=”655379″ placement=”ros”]As January comes to a close, we are in the heart of earnings season, when most companies report and set a direction for the market. Dow 20,000 has been reached but the markets could push even higher.
The health care sector has some of its biggest players reporting later this week, with one pharma giant’s report already out of the way. 24/7 Wall St. has put together a preview of what to expect from these major companies posting earnings on Thursday and Friday.
We have included what analysts are saying about each stock, as well as a recent trading history and the consensus price target.
Johnson & Johnson (NYSE: JNJ) released its fourth-quarter earnings report earlier this week. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.58 on revenue of $18.1 billion. In the same period a year ago, it reported EPS of $1.44 on revenue of $17.81 billion. Fourth-quarter results also compare to the consensus estimates for EPS of $1.56 on revenue of $18.28 billion. Shares were trading at $111.99 on Wednesday, with a consensus analyst price target of $125.47 and a 52-week trading range of $99.78 to $126.07.
[nativounit]
On Thursday, Biogen Inc. (NASDAQ: BIIB) reports its fourth-quarter financial results. The consensus estimates are calling for $4.96 in EPS and $2.94 billion in revenue. The same period of last year reportedly had EPS of $4.50and $2.84 billion in revenue. Shares of Biogen were trading at $275.70. The consensus price target is $340.51, and the 52-week range is $223.02 to $333.65.
Also scheduled to release its most recent earnings report on Thursday is Bristol-Myers Squibb Co. (NYSE: BMY). The consensus estimates are EPS of $0.67 and $5.13 billion in revenue. In the same period of last year, it posted $0.38 in EPS and revenue of $4.29 billion. Bristol-Myers shares were last seen at $49.25, with a 52-week range of $48.90 to $77.12 and a consensus price target of $59.06.
Celgene Corp. (NASDAQ: CELG) is set to report its fourth quarter results on Thursday as well. Thomson Reuters is calling for $1.59 in EPS and $3.02 billion in revenue. That compares with the $1.18 in EPS and $2.56 billion in revenue in the same period of last year. Celgene traded at $113.60. The stock has a 52-week range of $93.05 to $127.00 and a consensus price target of $138.63.
The on Friday, AbbVie Inc. (NYSE: ABBV) reports its fourth-quarter financial results. Analysts anticipate $1.19 in EPS and $6.92 billion in revenue, up from the $1.13 per share and $6.36 billion in the year-ago period. Shares of AbbVie were last seen at $61.40, with a consensus analyst target of $69.94 and a 52-week range of $51.60 to $68.12.
[wallst_email_signup]
Top Gaining Stocks
Top Losing Stocks